← All trials
NCT04438083
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 16, 2020
- Primary completion
- Feb 28, 2027
- Completion date
- Apr 30, 2027
- First posted
- Jun 18, 2020
- Last posted
- Jun 18, 2020
- Enrollment
- 95
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CRISPR TherapeuticsLead sponsor
- CRISPR TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.